Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Experimental Cell Lines for CAR T Therapies

publication date: Feb 20, 2019
 | 
author/source: AMS Biotechnology (Europe) Ltd

CAR T cells for treatment of leukemia and lymphoma


AMSBIO has added new experimental cell lines to its CAR T cell research range. 

Recent FDA approval of CAR T cells for treatment of leukemia and lymphoma has resulted in rapid growth in research on the therapeutic uses of such cells. The new AMSBIO experimental cell lines provide you with the power to screen antibodies and ligands against your target, enhancing your search for new CAR T therapies.

A therapeutic Chimeric Antigen Receptor (CAR) is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signaling domains derived from the TCR g chain, along with other costimulatory receptors. The scFv provides a specific binding domain that recognizes target proteins on cancer cells. A patient’s own T cells are isolated and activated, then transfected with a gene expressing the CAR. This reprograms the T cells to identify and attack tumor cells expressing the target protein, creating personalized immune cells designed to specifically target the patient’s cancer.

New stable CHO recombinant cell lines are available from AMSBIO for constitutively expressing full length human CD123, PSMA and ICOSL. Each stable clonal cell line was selected for different levels of expression to mimic different stages of cancer target cells with various CD123, PSMA or ICOSL expression levels.

At AMSBIO, we strive to provide tools at the cutting edge of cancer research. We produce a growing list of experimental cell lines, recombinant proteins and screening services to advance the search for new CAR T cell therapies. 

 

find out more

more news from this company



If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events